Approval from Health Canada to import Eptifibatide solution for infusion and injection

Juno Pharmaceuticals Canada is excited to announce that we have received approval from Health Canada to import Eptifibatide solution for infusion and injection (“Eptifibatide”) pursuant to Health Canada’s exceptional importation and sale guidelines. Juno has procured for immediate release a six-month to supply to the entirety of the Canadian market, helping to replenish a dangerously depleted supply.

 
  Eptifibatide is indicated for use in patients with certain types of acute coronary syndromes (diseases where blood flow to the heart decreases or is obstructed) while they are undergoing particular interventions, such as intracoronary stenting, to help prevent blood clotting. The drug has been in limited supply since October 2022, and over the last five months, some hospitals have needed to resort to less effective alternatives in its absence. According to Thrombosis Canada, blood clots are responsible for one-in-four deaths in Canada each year
.